Skip Nav Destination
Issues
15 April 2014
-
Cover Image
Cover Image
The cover shows a class of recurrent hotspot mutations in PIK3R1 and PIK3CA from endometrial cancer patients that are clustered at the interface between the iSH2 domain of PIK3R1 and the C2 domain of PIK3CA. Alteration of some of these crucial amino acids has been shown to be sufficient to disrupt the inhibitory contact by PIK3R1 and may represent a novel mechanism of oncogenic activation of PIK3CA. For details, see the article by Bourgon and colleagues on page 2080 of this issue. - PDF Icon PDF LinkTable of Contents
ISSN 1078-0432
EISSN 1557-3265
Highlights
CCR Translations
CCR Perspectives in Drug Approval
U.S. Food and Drug Administration Approval: Crizotinib for Treatment of Advanced or Metastatic Non–Small Cell Lung Cancer That Is Anaplastic Lymphoma Kinase Positive
Shakun M. Malik; Virginia Ellen Maher; Karen E. Bijwaard; Robert L. Becker; Lijun Zhang; Shenghui W. Tang; Pengfei Song; Qi Liu; Anshu Marathe; Brenda Gehrke; Whitney Helms; Diane Hanner; Robert Justice; Richard Pazdur
CCR Drug Updates
Molecular Pathways
Reviews
Human Cancer Biology
Author Choice
High-Throughput Detection of Clinically Relevant Mutations in Archived Tumor Samples by Multiplexed PCR and Next-Generation Sequencing
Richard Bourgon; Shan Lu; Yibing Yan; Mark R. Lackner; Weiru Wang; Victor Weigman; David Wang; Yinghui Guan; Lisa Ryner; Hartmut Koeppen; Rajesh Patel; Garret M. Hampton; Lukas C. Amler; Yulei Wang
Cancer Therapy: Preclinical
Antagonism of SET Using OP449 Enhances the Efficacy of Tyrosine Kinase Inhibitors and Overcomes Drug Resistance in Myeloid Leukemia
Anupriya Agarwal; Ryan J. MacKenzie; Raffaella Pippa; Christopher A. Eide; Jessica Oddo; Jeffrey W. Tyner; Rosalie Sears; Michael P. Vitek; María D. Odero; Dale J. Christensen; Brian J. Druker
Imaging, Diagnosis, Prognosis
Occurrence of Tertiary Lymphoid Tissue Is Associated with T-Cell Infiltration and Predicts Better Prognosis in Early-Stage Colorectal Cancers
Giuseppe Di Caro; Francesca Bergomas; Fabio Grizzi; Andrea Doni; Paolo Bianchi; Alberto Malesci; Luigi Laghi; Paola Allavena; Alberto Mantovani; Federica Marchesi
Hypermethylation of the GABRE∼miR-452∼miR-224 Promoter in Prostate Cancer Predicts Biochemical Recurrence after Radical Prostatectomy
Helle Kristensen; Christa Haldrup; Siri Strand; Kamilla Mundbjerg; Martin M. Mortensen; Kasper Thorsen; Marie Stampe Ostenfeld; Peter J. Wild; Christian Arsov; Wolfgang Goering; Tapio Visakorpi; Lars Egevad; Johan Lindberg; Henrik Grönberg; Søren Høyer; Michael Borre; Torben F. Ørntoft; Karina D. Sørensen
Cancer Therapy: Clinical
A Phase I/II, Multiple-Dose, Dose-Escalation Study of Siltuximab, an Anti-Interleukin-6 Monoclonal Antibody, in Patients with Advanced Solid Tumors
Eric Angevin; Josep Tabernero; Elena Elez; Steven J. Cohen; Rastilav Bahleda; Jean-Luc van Laethem; Christian Ottensmeier; Jose A. Lopez-Martin; Sally Clive; Florence Joly; Isabelle Ray-Coquard; Luc Dirix; Jean-Pascal Machiels; Neil Steven; Manjula Reddy; Brett Hall; Thomas A. Puchalski; Rajesh Bandekar; Helgi van de Velde; Brenda Tromp; Jessica Vermeulen; Razelle Kurzrock
First-In-Human Phase I Study of Lurbinectedin (PM01183) in Patients with Advanced Solid Tumors
María Elena Elez; Josep Tabernero; David Geary; Teresa Macarulla; S. Peter Kang; Carmen Kahatt; Arturo Soto-Matos Pita; Carlos Fernandez Teruel; Mariano Siguero; Martin Cullell-Young; Sergio Szyldergemajn; Mark J. Ratain
Ultra Low-Dose IL-2 for GVHD Prophylaxis after Allogeneic Hematopoietic Stem Cell Transplantation Mediates Expansion of Regulatory T Cells without Diminishing Antiviral and Antileukemic Activity
Alana A. Kennedy-Nasser; Stephanie Ku; Paul Castillo-Caro; Yasmin Hazrat; Meng-Fen Wu; Hao Liu; Jos Melenhorst; A. John Barrett; Sawa Ito; Aaron Foster; Barbara Savoldo; Eric Yvon; George Carrum; Carlos A. Ramos; Robert A. Krance; Kathryn Leung; Helen E. Heslop; Malcolm K. Brenner; Catherine M. Bollard
Preclinical and Early Clinical Evaluation of the Oral AKT Inhibitor, MK-2206, for the Treatment of Acute Myelogenous Leukemia
Marina Y. Konopleva; Roland B. Walter; Stefan H. Faderl; Elias J. Jabbour; Zhihong Zeng; Gautam Borthakur; Xuelin Huang; Tapan M. Kadia; Peter P. Ruvolo; Jennie B. Feliu; Hongbo Lu; LaKiesha Debose; Jan A. Burger; Michael Andreeff; Wenbin Liu; Keith A. Baggerly; Steven M. Kornblau; L. Austin Doyle; Elihu H. Estey; Hagop M. Kantarjian
Letters to the Editor
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.
RSS Feeds